Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.

In one double-blind, randomized controlled trial in which basimglurant, an mGlu5 receptor antagonist, was administered as an adjunctive treat- ment to ongoing SSRI or SNRI treatment, an antidepressant effect was observed in patients with MDD, as evaluated by secondary and exploratory endpoints (patient-rated Montgomery-Asberg Depression Scale (MADRS), Quick Inventory of Depressive Symptomatology-Self-Report), although the effect did not reach statistical significance when clinician-rated MADRS was used to assess the primary endpoint [ 89 ].

also in 111,027 other papers